Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Advance
  • Published:

Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?

Nature Reviews Cardiology volume 6, pages 168–169 (2009)Cite this article

Abstract

The POPADAD (Prevention Of Progression of Arterial Disease And Diabetes) study did not show a benefit for low-dose aspirin therapy or administration of antioxidants for the primary prevention of cardiovascular disease events in individuals with diabetes and asymptomatic peripheral arterial disease. Although low-dose aspirin continues to be recommended in international guidelines, no convincing trial-based evidence exists that supports its routine use for primary prevention of cardiovascular disease in people with diabetes. This paradox is unhelpful and the guidelines should be relaxed until definitive evidence becomes available.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. American Diabetes Association (2007) Standards of medical care in diabetes—2007. Diabetes Care 30 (Suppl 1): S4–S41

  2. Nicolucci A et al. (2007) AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 28: 1925–1927

    Article  CAS  Google Scholar 

  3. Belch J et al. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337: a1840

    Article  Google Scholar 

  4. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71–86

    Article  Google Scholar 

  5. Ogawa H et al. (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300: 2134–2141

    Article  CAS  Google Scholar 

  6. Natarajan A et al. (2008) Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents. Diab Vasc Dis Res 5: 138–144

    Article  Google Scholar 

  7. ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268: 1292–1300

Download references

Author information

Authors and Affiliations

  1. HC Price is a Specialist Registrar in diabetes and endocrinology, and a Clinical Research Fellow at the University of Oxford Diabetes Trials Unit. RR Holman is Professor of Diabetic Medicine at the University of Oxford, Director of the University of Oxford Diabetes Trials Unit, and an Honorary Consultant Physician to the Oxford Radcliffe Hospitals NHS Trust, Oxford, UK.,

    Hermione C Price & Rury R Holman

Authors
  1. Hermione C Price
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rury R Holman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rury R Holman.

Ethics declarations

Competing interests

RR Holman has received research support from Bayer. HC Price declared no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Price, H., Holman, R. Primary prevention of cardiovascular events in diabetes: is there a role for aspirin?. Nat Rev Cardiol 6, 168–169 (2009). https://doi.org/10.1038/ncpcardio1446

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1446

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing